Immatics N.V.
NASDAQ:IMTXBiotechnology
+$0.15 today
- Market cap
- $912.78M
- Beta
- 1.30
- P/E (TTM)
- -5.3
- EPS (TTM)
- -$1.59
Volume 1.57M
Average 0.46M
IMTX Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Immatics N.V.NASDAQ: IMTX
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow turns positive
Q1 FY2026 financing cash flow was €21.32M, compared with -€737K a year earlier. Trailing-twelve-month financing cash flow was €118.48M. Over 3 fiscal years it compounded at -8.9% a year.
Context
- Financing cash flow amounted to 193.7% of revenue in FY2025, down 11.4 pp from a year earlier.
- Financing cash flow increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly financing cash flow holds near €21.32M or moves back toward the trailing-twelve-month quarterly average of €29.62M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
EUR · from the cash flow
- Latest · FY2025
- 93.51M EUR
- Year-over-year change
- -70.7%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 93.51M | -70.7% |
| FY2024 | 2024-12-31 | 319.68M | +278.3% |
| FY2023 | 2023-12-31 | 84.52M | -31.7% |
| FY2022 | 2022-12-31 | 123.71M | +4834.4% |
| FY2021 | 2021-12-31 | (2.61M) | — |
Financing Cash Flow vs competitors
How IMTX compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -17.9% is the 6th highest of 11, against a peer median of +38.3%.
- Financing cash flow amounts to 317.7% of revenue for IMTX, versus a peer median of 25.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | €118.48M EUR | -17.9% | -8.9% | 317.7% | |
| LTM Sep 2026 | $115.15M USD | +822385.3% | — | 8.5% | |
| LTM Jun 2026 | €112.12M EUR | +142.6% | -67.0% | 4.2% | |
| LTM Mar 2026 | $102.13M USD | +7755.9% | +68.0% | 329441.9% | |
| LTM Mar 2026 | $85.22M USD | +305.0% | +0.1% | 189.1% | |
| LTM Mar 2026 | $37.29M USD | -71.1% | +117.0% | — | |
| LTM Mar 2026 | $19.3M USD | -44.7% | -32.8% | 83.4% | |
| LTM Mar 2026 | $17.39M USD | -123.8% | — | 25.5% | |
| LTM Mar 2026 | $10.47M USD | +121.3% | -60.2% | 2.7% | |
| LTM Mar 2026 | $7.94M USD | -98.0% | +114.7% | 36.7% | |
| LTM Mar 2026 | $189K USD | -99.9% | — | 2.1% | |
| Peer median (excluding IMTX) | — | +38.3% | +0.1% | 25.5% | |
Competitors are the stored peer set for IMTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (93.34M) | 37.51M | (94.65M) | 15.22M | (188.69M) |
| Depreciation & Amortization | 5.26M | 6.97M | 7.23M | 12.23M | 11.91M |
| Deferred Income Tax | 11.15M | 4.52M | 0 | 6.13M | 0 |
| Stock-Based Compensation | 26.4M | 22.57M | 20.71M | 17.64M | 0 |
| Change in Working Capital | (31.7M) | 37.26M | 81.63M | (163.88M) | (42.23M) |
| Accounts Receivables | 569K | (429K) | (2.98M) | (1.76M) | (232.45K) |
| Inventory | 0 | 0 | (84.24M) | 0 | 0 |
| Accounts Payables | (31.78M) | 45.56M | 84.24M | 0 | (36.13M) |
| Other Working Capital | (483K) | (7.87M) | 84.61M | (162.11M) | (5.87M) |
| Other Non-Cash Items | 433K | (8.7M) | 3.31M | (45.37M) | 49.36M |
| Operating Cash Flow | (81.78M) | 100.13M | 18.23M | (158.03M) | (169.66M) |
| Capital Expenditures | (5.66M) | (6.22M) | (30.96M) | (16.48M) | (6.3M) |
| Acquisitions (Net) | 551K | (199.91M) | 0 | 0 | 0 |
| Purchases of Investments | (11.3M) | (216.32M) | (415.33M) | (450.35M) | (324.92M) |
| Sales of Investments | 24.45M | 12.7M | 414.74M | 314.44M | 528.16M |
| Other Investing Activities | (551K) | 199.96M | (8K) | (206K) | 0 |
| Investing Cash Flow | 7.49M | (209.79M) | (31.39M) | (152.39M) | 196.7M |
| Debt Repayment | (2.71M) | (2.84M) | (3.85M) | (2.01M) | 0 |
| Common Stock Issued | 94K | 134.48M | 90.4M | 343.01M | 96.35M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (7.93M) | (2.04M) | (21.31M) | (2.84M) |
| Financing Cash Flow | (2.61M) | 123.71M | 84.52M | 319.68M | 93.51M |
| Effect of Forex Changes | 2.37M | 1.48M | (1.4M) | 9.01M | 16.56M |
| Net Change in Cash | (74.54M) | 15.53M | 69.95M | 18.28M | 137.12M |
| Free Cash Flow | (87.44M) | 93.92M | (12.73M) | (174.51M) | (175.95M) |
Immatics N.V.
NASDAQ:IMTX
Intrinsic Alpha fair value
Locked
Current Price
$6.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.